The NCAA men's basketball tournament bracket is out, and we'll probably get around to filling one out by Thursday. But we might go down to the wire this year because we've been spending a lot of time handicapping changes in the executive suites of Big Pharma and Big Biotech, the Wall Street Journal reports.
Restless shareholders, listless labs and a tidal wave of generic competition confront the top executives at drug makers around the globe. Big Biotech has plenty of problems of its own. Did we mention pushback on prices?
So we wonder who among the leaders of the current executive pack will win the test of endurance to remain the last CEO standing? Take a look at our second annual bracket by clicking on the image at the right. Feel free to start your own office pool.
Figuring this will be a long-running competition, we included a couple of CEOs-in-waiting: Andrew Witty at GlaxoSmithKline and John Lechleiter at Eli Lilly. As for Sanofi-Aventis, we just weren't sure whether to enter CEO G & #233;rard Le Fur or chairman Jean-Fran & #231;ois Dehecq.
Read the full Wall Street Journal story .(subscription required)
For reprint and licensing requests for this article, CLICK HERE.